Ionis Pharmaceuticals
Top View
- Hereditary Transthyretin Amyloidosis
- Objectives & Accreditation
- Cardiovascular Franchise Presentation
- First-In-Class Therapies Using Advanced Antisense Chemistries Highlighted at 2018 American Society of Hematology Annual Meeting
- Ionis' Antisense Technology to Be Featured During Virtual RNA at the Bench and Bedside II Conference
- AKCEA-ANGPTL3-Lrx) in Statin- Treated Patients with Elevated Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) and Triglycerides (Tgs)
- Medicine. Saving Lives
- Index Components (PDF)
- Fund Holdings
- 1St Quarter Report
- NPORT-EX 2 Lma2900cbvaraggressgrth.Htm CLEARBRIDGE VARIABLE AGGRESSIVE GROWTH PORTFOLIO
- October 2019
- Moderna 2021 Proxy Statement
- Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc
- Healthcare Sector Review September 2018
- Partnering to Improve Vision AMD, Age-Related Macular Degeneration; Enac,Epithelialsodiumchannel;IGF-1R, Insulin-Like Growth Factor 1Receptor; N/A, Notavailable
- Lipid Modification to Reduce Cardiovascular Risk: Are We Achieving Our Goals?
- Monthly Holdings